TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06553872: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06553872 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06553872 Rescue Dossier →